Revolution Medicines Presents Updated Phase 1/2 Data for RASONQUE® (daraxonrasib) Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer at ENA 2026
Key Highlights
- ➤RASONQUE plus GnP achieved a 60.7% confirmed objective response rate in 61 patients
- ➤Complete responses reached 8.2%, with disease control rate at 90.2%
- ➤Median progression-free survival was 12.8 months after 18.3 months’ median follow-up
- ➤Twelve-month overall survival was 76.6%, supporting the ongoing Phase 3 RASolute 303 trial
- ➤FDA granted Breakthrough Therapy Designation for RASONQUE plus GnP in first-line metastatic PDAC
Expert Statements
Wungki Park, M.D., M.S., medical oncologist at Memorial Sloan Kettering Cancer Center and RMC-GI-102 and RASolute 303 investigator
“With longer follow-up and a larger patient population, we are seeing a notable combination of high response rates, including deep complete responses, and durable disease control, with median progression-free survival exceeding one year.”
Wungki Park, M.D., M.S., medical oncologist at Memorial Sloan Kettering Cancer Center and RMC-GI-102 and RASolute 303 investigator
“The emerging survival signal is meaningful and is estimated at 76.6% for patients to be alive at one year.”
Wungki Park, M.D., M.S., medical oncologist at Memorial Sloan Kettering Cancer Center and RMC-GI-102 and RASolute 303 investigator
“Taken together, these findings provide a compelling rationale to further evaluate daraxonrasib as a potential first-line treatment option.”
Alan Sandler, M.D., chief development officer of Revolution Medicines
“People with treatment-naïve metastatic pancreatic cancer urgently need more effective treatment options, given the limited clinical benefit of current chemotherapy regimens.”
Alan Sandler, M.D., chief development officer of Revolution Medicines
“The FDA’s recent Breakthrough Therapy Designation for RASONQUE plus GnP in this setting underscores the urgency of this work.”
Alan Sandler, M.D., chief development officer of Revolution Medicines
“The durability of treatment shown with these updated Phase 1/2 results is particularly encouraging and supports the ongoing Phase 3 RASolute 303 trial, which is evaluating RASONQUE both as a monotherapy and in combination with GnP versus GnP alone in patients with treatment-naïve metastatic PDAC, independent of tumor RAS genotype.”
* With additional patients and longer follow-up, the combination of RASONQUE plus gemcitabine and nab-paclitaxel demonstrated deep and durable responses in the first-line treatment setting * Results support the ongoing Phase 3 RASolute 303 trial in patients with treatment-naïve metastatic pancreatic cancer REDWOOD CITY, Calif., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced encouraging updated results from the Phase 1/2 RMC-GI-102 open-label study evaluating RASONQUE (daraxonrasib) in combination with gemcitabine and nab-paclitaxel (GnP) as a potential first-line treatment for patients with metastatic pancreatic adenocarcinoma (PDAC). The data will be presented today during a late-breaking oral session at the EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.
Get started
Create a free account to read the full story.
